CRYAB and myeloid sarcoma: Based on these considerations and our Phase I data as illustrated in Fig 3, and despite the inconclusive outcome of CFSE assays performed during the Phase IIa study, we favor the idea that tolerance induction via antigen-specific regulatory T cells is an important contributing factor to the clinical effects of intravenous HspB5 in RR-MS patients.